Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer

• NASDAQ: $EXEL
• Notified: $23.15
• 08:01 EDT